Brief: Santhera Pharmaceuticals A Direct License Holder Of Vamorolone

Santhera Pharmaceuticals Holding AG

02/09/2020 06:04

Sept 2 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG
 SANN.S :
    * EXERCISES OPTION TO OBTAIN WORLDWIDE RIGHTS TO VAMOROLONE
IN
DUCHENNE MUSCULAR DYSTROPHY AND ALL OTHER INDICATIONS
    * ANNOUNCES THAT IT HAS SIGNED AGREEMENTS WITH IDORSIA (SIX:
IDIA)
AND REVERAGEN BIOPHARMA INC., MAKING SANTHERA A DIRECT LICENSE
HOLDER OF VAMOROLONE
    * EXPECTS A REDUCTION IN CASH OUTFLOW IN RANGE OF USD 18-24
MILLION IN NEXT 12-18 MONTHS
    * IN EXCHANGE FOR REVISED LICENSE RIGHTS, IDORSIA WILL
RECEIVE
366,667 SANTHERA SHARES AND AN EXCHANGEABLE NOTE IN AMOUNT OF
CHF 10 MILLION
    * REVERAGEN WILL RECEIVE USD 7 MILLION, IN MONTHLY
INSTALMENTS OF
UP TO USD 500,000, TO FUND ONGOING CLINICAL DEVELOPMENT OF
VAMOROLONE

Source text for Eikon:  ID:nGNE2k6RGQ 
Further company coverage:  SANN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;;))